{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:33:02Z","timestamp":1793975582747,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 is a newly emergent coronavirus, which has adversely impacted human health and has led to the COVID-19 pandemic. There is an unmet need to develop therapies against SARS-CoV-2 due to its severity and lack of treatment options. A promising approach to combat COVID-19 is through the neutralization of SARS-CoV-2 by therapeutic antibodies. Previously, we described a strategy to rapidly identify and generate llama nanobodies (VHH) from na\u00efve and synthetic humanized VHH phage libraries that specifically bind the S1 SARS-CoV-2 spike protein, and block the interaction with the human ACE2 receptor. In this study we used computer-aided design to construct multi-specific VHH antibodies fused to human IgG1 Fc domains based on the epitope predictions for leading VHHs. The resulting tri-specific VHH-Fc antibodies show more potent S1 binding, S1\/ACE2 blocking, and SARS-CoV-2 pseudovirus neutralization than the bi-specific VHH-Fcs or combination of individual monoclonal VHH-Fcs. Furthermore, protein stability analysis of the VHH-Fcs shows favorable developability features, which enable them to be quickly and successfully developed into therapeutics against COVID-19.<\/jats:p>","DOI":"10.1038\/s41598-020-74761-y","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T06:03:16Z","timestamp":1603173796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2"],"prefix":"10.1038","volume":"10","author":[{"given":"Jianbo","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Titong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachith","family":"Gallolu Kankanamalage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhejun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pannaga","family":"Parthasarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"74761_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3201\/eid2607.200841","volume":"26","author":"NMA Okba","year":"2020","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis. 26, 1478\u20131488. https:\/\/doi.org\/10.3201\/eid2607.200841 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"74761_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014Preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74761_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2601-5","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature https:\/\/doi.org\/10.1038\/s41586-020-2601-5 (2020).","journal-title":"Nature"},{"key":"74761_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273. https:\/\/doi.org\/10.1038\/s41586-020-2012-7 (2020).","journal-title":"Nature"},{"key":"74761_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra032498","volume":"349","author":"JS Peiris","year":"2003","unstructured":"Peiris, J. S., Yuen, K. Y., Osterhaus, A. D. & Stohr, K. The severe acute respiratory syndrome. N. Engl. J. Med. 349, 2431\u20132441. https:\/\/doi.org\/10.1056\/NEJMra032498 (2003).","journal-title":"N. Engl. J. Med."},{"key":"74761_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450\u2013454. https:\/\/doi.org\/10.1038\/nature02145 (2003).","journal-title":"Nature"},{"key":"74761_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","volume":"495","author":"VS Raj","year":"2013","unstructured":"Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251\u2013254. https:\/\/doi.org\/10.1038\/nature12005 (2013).","journal-title":"Nature"},{"key":"74761_CR8","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1128\/JVI.01085-07","volume":"82","author":"W Ren","year":"2008","unstructured":"Ren, W. et al. Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J. Virol. 82, 1899\u20131907. https:\/\/doi.org\/10.1128\/JVI.01085-07 (2008).","journal-title":"J. Virol."},{"key":"74761_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569. https:\/\/doi.org\/10.1038\/s41564-020-0688-y (2020).","journal-title":"Nat. Microbiol."},{"key":"74761_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature 584, 120\u2013124. https:\/\/doi.org\/10.1038\/s41586-020-2381-y (2020).","journal-title":"Nature"},{"key":"74761_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119. https:\/\/doi.org\/10.1038\/s41586-020-2380-z (2020).","journal-title":"Nature"},{"key":"74761_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295. https:\/\/doi.org\/10.1038\/s41586-020-2349-y (2020).","journal-title":"Nature"},{"key":"74761_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384. https:\/\/doi.org\/10.1016\/j.cell.2020.05.025 (2020).","journal-title":"Cell"},{"key":"74761_CR14","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","volume":"181","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 181, 1004\u20131015. https:\/\/doi.org\/10.1016\/j.cell.2020.04.031 (2020).","journal-title":"Cell"},{"key":"74761_CR15","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251. https:\/\/doi.org\/10.1038\/s41467-020-16256-y (2020).","journal-title":"Nat. Commun."},{"key":"74761_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","volume":"27","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27, 846\u2013854. https:\/\/doi.org\/10.1038\/s41594-020-0469-6 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74761_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib8010001","volume":"8","author":"D De Vlieger","year":"2018","unstructured":"De Vlieger, D., Ballegeer, M., Rossey, I., Schepens, B. & Saelens, X. Single-domain antibodies and their formatting to combat viral infections. Antibodies (Basel) 8, 1. https:\/\/doi.org\/10.3390\/antib8010001 (2018).","journal-title":"Antibodies (Basel)"},{"key":"74761_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1110\/ps.34602","volume":"11","author":"M Dumoulin","year":"2002","unstructured":"Dumoulin, M. et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 11, 500\u2013515. https:\/\/doi.org\/10.1110\/ps.34602 (2002).","journal-title":"Protein Sci."},{"key":"74761_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1080\/22221751.2020.1768806","volume":"9","author":"J Dong","year":"2020","unstructured":"Dong, J. et al. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2\/ACE2 interaction with high affinity and avidity. Emerg. Microbes Infect. 9, 1034\u20131036. https:\/\/doi.org\/10.1080\/22221751.2020.1768806 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"74761_CR20","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/prot.24551","volume":"82","author":"K Zhu","year":"2014","unstructured":"Zhu, K. et al. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction. Proteins 82, 1646\u20131655. https:\/\/doi.org\/10.1002\/prot.24551 (2014).","journal-title":"Proteins"},{"key":"74761_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/protein\/gzu017","volume":"27","author":"NK Salam","year":"2014","unstructured":"Salam, N. K., Adzhigirey, M., Sherman, W. & Pearlman, D. A. Structure-based approach to the prediction of disulfide bonds in proteins. Protein Eng. Des. Sel. 27, 365\u2013374. https:\/\/doi.org\/10.1093\/protein\/gzu017 (2014).","journal-title":"Protein Eng. Des. Sel."},{"key":"74761_CR22","doi-asserted-by":"publisher","first-page":"e82849","DOI":"10.1371\/journal.pone.0082849","volume":"8","author":"H Beard","year":"2013","unstructured":"Beard, H., Cholleti, A., Pearlman, D., Sherman, W. & Loving, K. A. Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexes. PLoS ONE 8, e82849. https:\/\/doi.org\/10.1371\/journal.pone.0082849 (2013).","journal-title":"PLoS ONE"},{"key":"74761_CR23","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1529\/biophysj.108.135814","volume":"95","author":"GY Chuang","year":"2008","unstructured":"Chuang, G. Y., Kozakov, D., Brenke, R., Comeau, S. R. & Vajda, S. DARS (Decoys As the Reference State) potentials for protein\u2013protein docking. Biophys. J. 95, 4217\u20134227. https:\/\/doi.org\/10.1529\/biophysj.108.135814 (2008).","journal-title":"Biophys. J."},{"key":"74761_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/prot.21117","volume":"65","author":"D Kozakov","year":"2006","unstructured":"Kozakov, D., Brenke, R., Comeau, S. R. & Vajda, S. PIPER: An FFT-based protein docking program with pairwise potentials. Proteins 65, 392\u2013406. https:\/\/doi.org\/10.1002\/prot.21117 (2006).","journal-title":"Proteins"},{"key":"74761_CR25","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1002\/prot.22801","volume":"78","author":"J Fern\u00e1ndez-Recio","year":"2010","unstructured":"Fern\u00e1ndez-Recio, J. & Sternberg, M. J. E. The 4th meeting on the Critical Assessment of Predicted Interaction (CAPRI) held at the Mare Nostrum, Barcelona. Proteins Struct. Funct. Bioinform. 78, 3065\u20133066. https:\/\/doi.org\/10.1002\/prot.22801 (2010).","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"74761_CR26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278. https:\/\/doi.org\/10.1126\/science.abc2241 (2020).","journal-title":"Science"},{"key":"74761_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-3527(08)60286-9","volume":"48","author":"MM Lai","year":"1997","unstructured":"Lai, M. M. & Cavanagh, D. The molecular biology of coronaviruses. Adv. Virus Res. 48, 1\u2013100 (1997).","journal-title":"Adv. Virus Res."},{"key":"74761_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nsmb1123","volume":"13","author":"DR Beniac","year":"2006","unstructured":"Beniac, D. R., Andonov, A., Grudeski, E. & Booth, T. F. Architecture of the SARS coronavirus prefusion spike. Nat. Struct. Mol. Biol. 13, 751\u2013752. https:\/\/doi.org\/10.1038\/nsmb1123 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74761_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263. https:\/\/doi.org\/10.1126\/science.abb2507 (2020).","journal-title":"Science"},{"key":"74761_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/abt\/tbaa008","volume":"3","author":"LL Xin Zeng","year":"2020","unstructured":"Xin Zeng, L. L. et al. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy. Antibody Therap. 3, 95\u2013100 (2020).","journal-title":"Antibody Therap."},{"key":"74761_CR31","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","volume":"24","author":"M Bacac","year":"2018","unstructured":"Bacac, M. et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin. Cancer Res. 24, 4785\u20134797. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0455 (2018).","journal-title":"Clin. Cancer Res."},{"key":"74761_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.chom.2010.01.004","volume":"7","author":"RM Zellweger","year":"2010","unstructured":"Zellweger, R. M., Prestwood, T. R. & Shresta, S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7, 128\u2013139. https:\/\/doi.org\/10.1016\/j.chom.2010.01.004 (2010).","journal-title":"Cell Host Microbe"},{"key":"74761_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","volume":"20","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 339\u2013341. https:\/\/doi.org\/10.1038\/s41577-020-0321-6 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"74761_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1126\/science.7041255","volume":"215","author":"J Holland","year":"1982","unstructured":"Holland, J. et al. Rapid evolution of RNA genomes. Science 215, 1577\u20131585. https:\/\/doi.org\/10.1126\/science.7041255 (1982).","journal-title":"Science"},{"key":"74761_CR35","doi-asserted-by":"publisher","first-page":"e01031","DOI":"10.1128\/JVI.01031-17","volume":"92","author":"KM Peck","year":"2018","unstructured":"Peck, K. M. & Lauring, A. S. Complexities of viral mutation rates. J. Virol. 92, e01031-e1117. https:\/\/doi.org\/10.1128\/JVI.01031-17 (2018).","journal-title":"J. Virol."},{"key":"74761_CR36","doi-asserted-by":"publisher","first-page":"157895","DOI":"10.1155\/2014\/157895","volume":"2014","author":"PJ Klasse","year":"2014","unstructured":"Klasse, P. J. Neutralization of virus infectivity by antibodies: Old problems in new perspectives. Adv. Biol. 2014, 157895. https:\/\/doi.org\/10.1155\/2014\/157895 (2014).","journal-title":"Adv. Biol."},{"key":"74761_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21037\/atm.2019.01.42","volume":"7","author":"C Lo Nigro","year":"2019","unstructured":"Lo Nigro, C. et al. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: Biological evidence and clinical perspectives. Ann. Transl. Med. 7, 105. https:\/\/doi.org\/10.21037\/atm.2019.01.42 (2019).","journal-title":"Ann. Transl. Med."},{"key":"74761_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12026-014-8542-z","volume":"59","author":"LM Rogers","year":"2014","unstructured":"Rogers, L. M., Veeramani, S. & Weiner, G. J. Complement in monoclonal antibody therapy of cancer. Immunol. Res. 59, 203\u2013210. https:\/\/doi.org\/10.1007\/s12026-014-8542-z (2014).","journal-title":"Immunol. Res."},{"key":"74761_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","volume":"10","author":"MZ Tay","year":"2019","unstructured":"Tay, M. Z., Wiehe, K. & Pollara, J. Antibody-dependent cellular phagocytosis in antiviral immune responses. Front. Immunol. 10, 332. https:\/\/doi.org\/10.3389\/fimmu.2019.00332 (2019).","journal-title":"Front. Immunol."},{"key":"74761_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","volume":"10","author":"EA van Erp","year":"2019","unstructured":"van Erp, E. A., Luytjes, W., Ferwerda, G. & van Kasteren, P. B. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front. Immunol. 10, 548. https:\/\/doi.org\/10.3389\/fimmu.2019.00548 (2019).","journal-title":"Front. Immunol."},{"key":"74761_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12977-018-0439-9","volume":"15","author":"NN Padte","year":"2018","unstructured":"Padte, N. N., Yu, J., Huang, Y. & Ho, D. D. Engineering multi-specific antibodies against HIV-1. Retrovirology 15, 60. https:\/\/doi.org\/10.1186\/s12977-018-0439-9 (2018).","journal-title":"Retrovirology"},{"key":"74761_CR42","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/jps.24430","volume":"104","author":"A Jarasch","year":"2015","unstructured":"Jarasch, A. et al. Developability assessment during the selection of novel therapeutic antibodies. J. Pharm. Sci. 104, 1885\u20131898. https:\/\/doi.org\/10.1002\/jps.24430 (2015).","journal-title":"J. Pharm. Sci."},{"key":"74761_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/19420862.2018.1553476","volume":"11","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs 11, 239\u2013264. https:\/\/doi.org\/10.1080\/19420862.2018.1553476 (2019).","journal-title":"MAbs"}],"updated-by":[{"DOI":"10.1038\/s41598-021-82913-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74761-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74761-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74761-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T16:55:17Z","timestamp":1670345717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74761-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74761"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74761-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-45225\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-82913-x","URL":"https:\/\/doi.org\/10.1038\/s41598-021-82913-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors of this study are employees of Ab Studio Inc. Yue Liu also serves as the Chief Executive Officer of Ab Therapeutics Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17806"}}